Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Breast Neoplasms 17Carcinoma, Renal Cell 14Neoplasms 12Neoplasm Metastasis 9Neuroendocrine Tumors 7Head and Neck Neoplasms 7Kidney Neoplasms 6Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Insulinoma 2Hodgkin Disease 2

Interventions

Bortezomib 2Vorinostat 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Subcutaneous panniculitis-like T-cell lymphoma × Everolimus × Clear all
NCT00671112 2015-10-28

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
30 enrolled
DermatologicLymphoidOther hematologic neoplasm

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡